Tectonic Therapeutic (TECX) EBITDA (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of EBITDA data on file, last reported at -$27.3 million in Q1 2026.

• On a quarterly basis, EBITDA fell 49.2% year-over-year to -$27.3 million in Q1 2026; TTM through Mar 2026 was -$93.0 million, a 46.87% decrease from a year earlier, with the FY2025 full-year figure at -$84.0 million, down 44.85% from the prior year.
• EBITDA for Q1 2026 stood at -$27.3 million, down from -$21.5 million in the prior quarter.
• Over the last five years, EBITDA for TECX reached as high as -$9.4 million in Q4 2023 and fell as low as -$29.4 million in Q1 2022.
• Historically, EBITDA has averaged -$19.4 million across 5 years, with a median of -$21.5 million in 2025.
• Across the five-year window, EBITDA jumped 62.89% in 2023 and slumped 95.53% in 2025, its largest moves.
• Year by year, EBITDA stood at -$25.3 million in 2022, then soared by 62.89% to -$9.4 million in 2023, then plunged by 49.25% to -$14.0 million in 2024, then tumbled by 53.78% to -$21.5 million in 2025, then dropped by 26.89% to -$27.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$27.3 million in Q1 2026, -$21.5 million in Q4 2025, and -$21.9 million in Q3 2025.